Our Work
Latham Advises Tyra Biosciences on US$200 Million Private Placement Financing
February 2, 2024
Firm represents the biotechnology company in the financing.
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, has announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately US$200 million.
Latham & Watkins LLP advised Tyra Biosciences in the financing with a corporate team led by San Diego partners Matt Bush and Cheston Larson, with associates Nadia Patiño and Rachel Staub.